中国70年来首次批准甲状腺眼病新注射,现为全国报销。 China approves first new thyroid eye disease injection in 70 years, now reimbursed nationally.

中国制药公司已获准使用新的甲状腺眼病注射,这是70多年来首次使用甲状腺眼病注射,现已列入国家报销清单,使治疗费用更低。 Chinese pharmaceutical companies have gained approval for a new thyroid eye disease injection—the first in over 70 years—now included in the national reimbursement list, making treatment more affordable. 这一里程碑突出了在监管改革、投资和人才的支持下,随着中国生物制药部门的扩大和加强全球竞争力,药物开发方面的国内创新在不断增长。 The milestone highlights growing domestic innovation in drug development, supported by regulatory reforms, investment, and talent, as China’s biopharmaceutical sector expands and strengthens global competitiveness.